NCT04550442View on ClinicalTrials.gov

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic SyndromeTherapy-Related Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given IV or SC

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT04550442 - Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Biotech Hunter | Biotech Hunter